Biotech week ahead, Jan. 27

Biotech stocks haven’t seen much of a momentum thus far in the new year amid a lack of meaningful catalysts. The bygone week saw two FDA approvals: Horizon Therapeutics PLC’s HZNP 2.83% thyroid eye disorder drug and Epizyme Inc’s EPZM 16.17% tazemetostat for epithelioid sarcoma.
The Wuhan coronavirus scare triggered strong moves in stocks of companies working on treatment/vaccines for the deadly virus.
Here are the key catalysts that could impact trading in biotech stocks in the unfolding week.

Conferences

12th Annual T-cell Lymphoma Forum: Jan. 30–Feb. 1 in San Diego, California

PDUFA Dates

Aimmune Therapeutics Inc AIMT 1.15% has a target action date of end of January for its peanut allergy treatment candidate Palforzia. An Adcom that evaluated the experimental therapy voted 7-to-2 in favor of the efficacy of Palforzia and 8-to-1 in favor of its safety.

Clinical Readouts

Miragen Therapeutics Inc MGEN 42.67% will make a poster presentation of data from the Phase 1 trial of cobomarsen, a miR inhibitor in patients with aggressive HTLV-1 Associated adult T-cell leukemia/lymphoma. The presentation is scheduled for Friday evening.

Earnings

Tuesday

• Pfizer Inc. PFE 2.17% (before the market open)

Wednesday

• Illumina, Inc. ILMN 2.27% (after the market close)
• Varian Medical Systems, Inc. VAR 0.74% (after the market close)
• Hologic, Inc. HOLX 0.19%

Thursday

• Quest Diagnostics Inc DGX 0.13% (before the market open)
• Eli Lilly And Co LLY 1.48% (before the market open)
• Biogen Inc BIIB 2.14% (before the market open)
• Amgen, Inc. AMGN 4.02% (after the market close)
• Edwards Lifesciences Corp EW 0.3% (after the market close)

IPOs

Anpac Bio-Medical Science, which focuses on early cancer screening and detection, has filed to offer 17.50 million shares in an IPO, which is expected to be priced between $14 and $16. The company is seeking to list its shares on the Nasdaq under the ticker symbol “ANPC.”
Arcutis Biotherapeutics, a biotech company developing topical therapies for common skin diseases, proposes to offer 7.8 million shares at a price range of $15-$17. The shares are to be listed on the Nasdaq under the ticker symbol “ARQT.”
Black Diamond Therapeutics, a precision oncology company, is planning an 8.9-million share IPO to be priced between $16 and $18. The company expects to list the shares on the Nasdaq under the ticker symbol “BDTX.”
https://www.benzinga.com/general/biotech/20/01/15181472/the-week-ahead-in-biotech-amgen-eli-lilly-pfizer-in-earnings-mix-ipo-flow-resumes